Decibel Therapeutics DBTX Stock
Decibel Therapeutics Price Chart
Decibel Therapeutics DBTX Financial and Trading Overview
Decibel Therapeutics stock price | 4.91 USD |
Previous Close | 4.54 USD |
Open | 4.66 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 800 |
Day's Range | 4.36 - 4.6 USD |
52 Week Range | 1.61 - 5.78 USD |
Volume | 19.85K USD |
Avg. Volume | 29.55K USD |
Market Cap | 109.07M USD |
Beta (5Y Monthly) | -0.133607 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.4 USD |
DBTX Valuation Measures
Enterprise Value | 32.83M USD |
Trailing P/E | N/A |
Forward P/E | -2.3315508 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.4764646 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.524 |
Trading Information
Decibel Therapeutics Stock Price History
Beta (5Y Monthly) | -0.133607 |
52-Week Change | 89.56% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.78 USD |
52 Week Low | 1.61 USD |
50-Day Moving Average | 3.61 USD |
200-Day Moving Average | 3.49 USD |
DBTX Share Statistics
Avg. Volume (3 month) | 29.55K USD |
Avg. Daily Volume (10-Days) | 22.29K USD |
Shares Outstanding | 25.02M |
Float | 11.78M |
Short Ratio | 3.11 |
% Held by Insiders | 14.99% |
% Held by Institutions | 70.72% |
Shares Short | 96.42K |
Short % of Float | 0.57% |
Short % of Shares Outstanding | 0.38% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -28.17% |
Return on Equity (ttm) | -62.93% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -62624000 USD |
Net Income Avi to Common (ttm) | -62293000 USD |
Diluted EPS (ttm) | -2.36 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 87.94M USD |
Total Cash Per Share (mrq) | 3.72 USD |
Total Debt (mrq) | 13.4M USD |
Total Debt/Equity (mrq) | 19.18 USD |
Current Ratio (mrq) | 4.136 |
Book Value Per Share (mrq) | 2.953 |
Cash Flow Statement
Operating Cash Flow (ttm) | -51947000 USD |
Levered Free Cash Flow (ttm) | -21852876 USD |
Profile of Decibel Therapeutics
Country | United States |
State | MA |
City | Boston |
Address | 1325 Boylston Street |
ZIP | 02215 |
Phone | 617 370 8701 |
Website | https://www.decibeltx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 68 |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Q&A For Decibel Therapeutics Stock
What is a current DBTX stock price?
Decibel Therapeutics DBTX stock price today per share is 4.91 USD.
How to purchase Decibel Therapeutics stock?
You can buy DBTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Decibel Therapeutics?
The stock symbol or ticker of Decibel Therapeutics is DBTX.
Which industry does the Decibel Therapeutics company belong to?
The Decibel Therapeutics industry is Biotechnology.
How many shares does Decibel Therapeutics have in circulation?
The max supply of Decibel Therapeutics shares is 25.13M.
What is Decibel Therapeutics Price to Earnings Ratio (PE Ratio)?
Decibel Therapeutics PE Ratio is 0.00000000 now.
What was Decibel Therapeutics earnings per share over the trailing 12 months (TTM)?
Decibel Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Decibel Therapeutics company belong to?
The Decibel Therapeutics sector is Healthcare.
Decibel Therapeutics DBTX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}